NXTCL — NextCell Pharma AB Income Statement
0.000.00%
Last trade - 00:00
- SEK43.15m
- SEK12.75m
- SEK10.11m
R2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.81 | 3.56 | 3.91 | 5.59 | 10.1 |
Cost of Revenue | |||||
Gross Profit | -3.8 | -3.2 | -6.03 | -3.13 | -0.885 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 19.8 | 21.3 | 28.7 | 40.6 | 51.1 |
Operating Profit | -18 | -17.7 | -24.8 | -35 | -41 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -18 | -17.7 | -24.6 | -34.6 | -39.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -18 | -17.7 | -24.6 | -34.6 | -39.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -18 | -17.7 | -24.6 | -34.6 | -39.8 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18 | -17.7 | -24.6 | -34.6 | -39.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.3 | -0.798 | -0.714 | -1.01 | -1.16 |
Dividends per Share |